Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824169 | 0.98 | CYP2A6 (0.50) | CYP2A6KDM1ARCOR1OPRL1SLC6A3 | |
| SCHEMBL14156408 | 0.84 | SLC6A4 (0.44) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL26208919 | 0.82 | SLC6A4 (0.43) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL761315 | 0.80 | CYP2A6 (0.52) | CYP2A6KDM1ARCOR1SLC6A3SLC6A4 | |
| SCHEMBL824170 | 0.79 | MAP3K14 (0.46) | CYP2A6PDK2MAP3K14 | |
| SCHEMBL12877797 | 0.79 | CYP2A6 (0.50) | CYP2A6KDM1ARCOR1SLC6A3SLC6A4 | |
| SCHEMBL3248838 | 0.79 | CYP2A6 (0.50) | CYP2A6KDM1ARCOR1SLC6A3SLC6A4 | |
| SCHEMBL2496770 | 0.78 | POLB (0.49) | CYP2A6LMNAMAPT | |
| SCHEMBL3973547 | 0.78 | POLB (0.49) | CYP2A6KDM1ARCOR1DHFRTYMS | |
| SCHEMBL12164924 | 0.77 | CYP2A6 (0.41) | CYP2A6KDM1ARCOR1OPRL1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090256468-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-15 | — | — | US | disclosed |
| US-20090256468-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-15 | — | — | US | disclosed |
| EP-2096108-A1 | Novel organic electroluminescent compounds and organic electroluminscent device using the same | Gracel Display Inc. (KR) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090256468-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD1, OCIAD2 | CYP2A6 1875/4885KDM1A 2854/4885RCOR1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.